Glucosamine: evidence grade C+, dosage & worth it

What it does

Glucosamine is an amino sugar the body uses to build glycosaminoglycans, the water-holding molecules that give cartilage its compressive cushioning. Supplements are sold as glucosamine sulfate (including a patented crystalline form), glucosamine hydrochloride, and N-acetyl glucosamine. The proposed mechanism is substrate supply for cartilage matrix plus mild anti-inflammatory effects seen in laboratory studies; whether oral doses meaningfully reach or rebuild human cartilage is unresolved.

What the research says

May modestly reduce knee osteoarthritis pain, with the clearest signals in moderate-to-severe pain and for the crystalline sulfate form
Evidence: moderate. The record is split. The NIH-funded GAIT trial (Clegg et al., N Engl J Med 2006, PMID 16495392; 1,583 patients) found glucosamine hydrochloride 1,500 mg/day no better than placebo overall, though the combination beat placebo in the moderate-to-severe subgroup (79.2% vs 54.3% responders). The MOVES trial (Hochberg et al., Ann Rheum Dis 2016) found glucosamine plus chondroitin non-inferior to celecoxib in severe knee OA. A BMJ network meta-analysis (Wandel et al., 2010) found no clinically relevant pain effect for glucosamine overall.
May slow joint space narrowing (cartilage loss on X-ray) over 2 to 3 years
Evidence: emerging. Two 3-year trials of crystalline glucosamine sulfate 1,500 mg/day found less joint space loss than placebo (Reginster et al., Lancet 2001;357:251-256, n=212; Pavelka et al., Arch Intern Med 2002;162:2113-2123, n=202), and the LEGS trial (Fransen et al., Ann Rheum Dis 2015) found a small structural benefit for the glucosamine-chondroitin combination (0.10 mm less narrowing over 2 years). Both 3-year trials were industry-linked, the absolute differences are fractions of a millimetre, and the 2-year GAIT ancillary study found no significant structural effect.
Regular use is associated with lower all-cause and cardiovascular mortality in large observational cohorts
Evidence: emerging. In the UK Biobank cohort of 495,077 adults, regular glucosamine use was associated with adjusted hazard ratios of 0.85 for all-cause and 0.82 for cardiovascular mortality over a median 8.9 years (Li et al., Ann Rheum Dis 2020;79:829-836, PMID 32253185). Similar associations appear in the US VITAL cohort (about 77,000 adults) and an NHANES analysis. These are observational data with likely healthy-user confounding; no randomized trial has tested mortality, so this is a hypothesis, not a demonstrated benefit.

Few supplements have been studied more, and few verdicts are more split. The largest independent trial (GAIT, NIH-funded) was null for the hydrochloride form, and the BMJ network meta-analysis found no clinically relevant effect on pain or joint space narrowing. The positive trials cluster around one patented crystalline sulfate preparation and were largely industry-funded (Reginster 2001, Pavelka 2002), with small structural effects of uncertain clinical meaning. Guidelines mirror the split: ESCEO's 2019 algorithm strongly recommends crystalline glucosamine sulfate as step-1 background therapy, while the American College of Rheumatology (2019) strongly recommends against glucosamine for knee, hip, and hand OA, citing publication bias. Safety is excellent and the observational mortality signal is consistent, but on trial evidence for its actual indication this is a small, form-dependent, contested benefit: C+.

What the experts say

Every position links to its source. We include skeptics alongside supporters.

Bryan Johnson
Source, 2026-09-10 Takes 750 mg/day of glucosamine sulfate in his Blueprint Longevity Mix, in the morning before training, per the published Blueprint protocol (compiled in our expert-stacks.json). Note this is half the 1,500 mg/day dose used in the osteoarthritis trials.

Is it worth it?

C+

Evidence (C+) sits below the leaderboard floor, so the worth-it grade is capped at C+ however inexpensive it is. About $15 a month at a common dose. Derived from the October 2026 worth-it model.

Typical cost

$10-20/month

Common form, not a brand recommendation

Dosage contextestablished

1,500 mg/day is the standard studied dose: crystalline glucosamine sulfate once daily, or glucosamine hydrochloride 500 mg three times daily (the GAIT regimen). Symptom effects, when they occur, take 4 to 8 weeks or longer; structural trials ran 2 to 3 years. Results from sulfate trials should not be assumed to transfer to the hydrochloride form.

Safety notes

Adverse events in trials are similar to placebo; mild gastrointestinal upset is the most common complaint. The one interaction that matters is warfarin: case reports and about 20 FDA MedWatch reports link glucosamine (often with chondroitin) to increased INR in previously stable warfarin patients (Knudsen and Sokol, Pharmacotherapy 2008), so anyone on warfarin should only use it with INR monitoring and their prescriber's knowledge. The shellfish warning is largely a myth: the allergenic protein (tropomyosin) is in shellfish meat, not the shells glucosamine is extracted from, and challenge testing in shellfish-allergic patients found shrimp-derived glucosamine well tolerated (Gray et al., J Allergy Clin Immunol 2004;114:459-460), though rare hypersensitivity reports mean severe-allergy patients should still be cautious or choose fermentation-derived products. Despite early concern from animal infusion studies, systematic reviews of human trials find no effect of oral glucosamine at usual doses on fasting glucose, HbA1c, or insulin sensitivity, including in people with type 2 diabetes.

Longevity Lab Report

Glucosamine news, graded when it happens.

The grade on this page stays free. The email carries the news on glucosamine: expert moves, dose changes, and what is working, in plain English every Thursday.

Frequently asked questions

Is Glucosamine safe?

Adverse events in trials are similar to placebo; mild gastrointestinal upset is the most common complaint. The one interaction that matters is warfarin: case reports and about 20 FDA MedWatch reports link glucosamine (often with chondroitin) to increased INR in previously stable warfarin patients (Knudsen and Sokol, Pharmacotherapy 2008), so anyone on warfarin should only use it with INR monitoring and their prescriber's knowledge. The shellfish warning is largely a myth: the allergenic protein (tropomyosin) is in shellfish meat, not the shells glucosamine is extracted from, and challenge testing in shellfish-allergic patients found shrimp-derived glucosamine well tolerated (Gray et al., J Allergy Clin Immunol 2004;114:459-460), though rare hypersensitivity reports mean severe-allergy patients should still be cautious or choose fermentation-derived products. Despite early concern from animal infusion studies, systematic reviews of human trials find no effect of oral glucosamine at usual doses on fasting glucose, HbA1c, or insulin sensitivity, including in people with type 2 diabetes.

What is the right dose of Glucosamine?

1,500 mg/day is the standard studied dose: crystalline glucosamine sulfate once daily, or glucosamine hydrochloride 500 mg three times daily (the GAIT regimen). Symptom effects, when they occur, take 4 to 8 weeks or longer; structural trials ran 2 to 3 years. Results from sulfate trials should not be assumed to transfer to the hydrochloride form.

Is Glucosamine worth taking?

We grade Glucosamine C+ for worth-it at a typical cost of $10-20 per month. Evidence (C+) sits below the leaderboard floor, so the worth-it grade is capped at C+ however inexpensive it is. About $15 a month at a common dose. Derived from the October 2026 worth-it model.

What do experts say about Glucosamine?

Bryan Johnson: Takes 750 mg/day of glucosamine sulfate in his Blueprint Longevity Mix, in the morning before training, per the published Blueprint protocol (compiled in our expert-stacks.json). Note this is half the 1,500 mg/day dose used in the osteoarthritis trials.